Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Akebia Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get AKBA alerts

About Erik Ostrowski

Erik Ostrowski is recorded as CFO at Akebia Therapeutics, Inc. (AKBA) and CEO at Tectonic Therapeutic, Inc. (TECX) since May 1, 2023. The newest filing on record that lists Erik Ostrowski as CFO at Akebia Therapeutics, Inc. (AKBA) is dated April 28, 2026. Akebia Therapeutics, Inc. reported in an 8-K filed June 24, 2024 that Erik Ostrowski was appointed Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024. Tectonic Therapeutic, Inc. reported in an 8-K filed June 20, 2024 that Erik Ostrowski resigned as President, Interim Chief Executive Officer and Chief Financial Officer (principal executive officer, principal financial officer, effective June 20, 2024. Tectonic Therapeutic, Inc. reported in an 8-K filed May 1, 2023 that Erik Ostrowski was appointed President and Interim Chief Executive Officer, effective May 1, 2023. The proxy statement of Akebia Therapeutics, Inc. reports total compensation of $1,792,361 for Erik Ostrowski in fiscal 2025, including a base salary of $552,919. Disclosed compensation is on record for 7 fiscal years. Erik Ostrowski has spoken on 5 earnings calls across 1 company, most recently for Akebia Therapeutics, Inc. on November 5, 2026. Akebia Therapeutics, Inc. is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Tectonic Therapeutic, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Akebia Therapeutics, Inc. includes John Butler (CEO, CFO and Board Member), John P. Butler (CEO and Board Member), Ellen Snow (CFO) and 7 others.

“On June 24, 2024, Akebia Therapeutics, Inc. (the "Company") announced the appointment of Erik Ostrowski as the Company's Senior Vice President, Chief Financial Officer, Chief Business Officer, Treasurer and principal financial officer, effective June 24, 2024 (the "Effective Date").”
Akebia Therapeutics, Inc. Form 8-K, filed June 24, 2024 · Read the filing
“Immediately prior to the Merger, Erik Ostrowski, Steven Avruch, Azadeh Golipour, Ph.D. and Essra Ridha, M.D., MRCP, FFPM resigned from all of their offices with AVROBIO and all of its subsidiaries, if applicable, including, with respect to Mr. Ostrowski, as AVROBIO's President, Interim Chief Executive Officer and Chief Financial Officer (principal executive officer, principal financial officer and principal accounting officer).”
Tectonic Therapeutic, Inc. Form 8-K, filed June 20, 2024 · Read the filing

Erik Ostrowski on recent calls

“Total revenues decreased to $36.9 million in Q326 from $58.8 million in Q325.”
CFO, Akebia’s Third Quarter 2026 Financial Results ·
“Total revenues were $49.1 million in Q2 26 compared to $62.5 million in Q2 25. This decrease was due to lower Eryxia revenues, which were partially offset by higher VAPTIO.”
Other, Akebia Therapeutics, Inc. Q2 FY2026 Earnings Call ·
“We're pleased to deliver a Vastio revenue growth this quarter as we continue our pursuit to make Vastio a standard of care for the treatment of anemia and dialysis patients with CKD.”
CFO, Akebia Therapeutics, Inc. Q1 FY2026 Earnings Call ·
“As John mentioned, we saw a strong top-line performance in calendar year 25, as net product revenues increased nearly 50% over calendar year 24, driven by the U.S. introduction of Vasio and increased sales of Rixia.”
CFO, Akebia Therapeutics, Inc. Q4 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Akebia Therapeutics, Inc.

Leadership on record at Tectonic Therapeutic, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Akebia Therapeutics, Inc. (AKBA) $552,919 $1,792,361
2024 Akebia Therapeutics, Inc. (AKBA) $284,414 $1,215,122
2024 Tectonic Therapeutic, Inc. (TECX) $254,125 $1,093,258
2023 Tectonic Therapeutic, Inc. (TECX) $504,400 $1,590,892
2022 Tectonic Therapeutic, Inc. (TECX) $460,000 $1,352,093
2021 Tectonic Therapeutic, Inc. (TECX) $439,254 $2,705,607
2020 Tectonic Therapeutic, Inc. (TECX) $424,400 $2,010,017
2019 Tectonic Therapeutic, Inc. (TECX) $412,000 $2,753,795

Recent activity